The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions.If you have any queries about the SPCs on our website then please e-mail

Aderexa 12.5 mg/125 mg chewable tablets for dogs weighing at least 5 kg

12.5, 125.0 mg/tablet Chewable tablet

Krka, d.d., Novo mestoVPA10774/063/002

Main Information

Trade NameAderexa 12.5 mg/125 mg chewable tablets for dogs weighing at least 5 kg
Active SubstancesMilbemycin oxime
Strength12.5, 125.0 mg/tablet
Dosage FormChewable tablet
Licence HolderKrka, d.d., Novo mesto
Licence NumberVPA10774/063/002

Group Information

ATC CodeQP54AB51 milbemycin oxime, combinations
Therapeutic ClassEndoparasiticide


Licence Issued27/07/2018
Legal StatusPOM: Prescription Only Medicine as defined in relevant national legislation


Summary of Product CharacteristicsPDF Version
Package LeafletNo document available
Public Assessment ReportPDF Version
« Back